Kornimate/medical-research-clean huggingface dataset:
hpv vaccine immunity in high-risk women

Conditions: HPV Infection

Summary: this is a single arm immunological study based in vietnam. the study will examine human papillomavirus (hpv) vaccine responses in high-risk women (female-sex-worker; fsw). we aim to recruit 60 women (aged 18-25 years old) and provide them with a standard 3-dose schedule of licensed 4vhpv vaccine (gardasil®, merck). blood and cervical swab samples will be collected for immunology and virology testing, respectively.

multiple sexual partners (\>4) is a risk factor for human papillomavirus (hpv) infection and cervical cancer. due to the nature of their work, female sex workers (fsw) are at a particular high risk of hpv infection and developing cervical cancer. these groups are also likely to be reservoirs for hpv transmission since they are less likely to clear the infection and are known to be infected with multiple hpv types simultaneously. benefits in vaccinating hpv-infected individuals, includes protecting them against hpv vaccine types that the person is not currently infected with as well as re-infection with the same hpv type. therefore, immunising fsw with hpv vaccine is a novel strategy to reduce their risk of cervical cancer as well as downstream effects on hpv transmission. fsw is common in low-and middle-income countries (lmics) of asia (i.e. vietnam), but the use of hpv vaccine in lmics is very low often due to high costs and logistical difficulties in vaccine delivery. furthermore, available data on the immunogenicity of hpv vaccine in fsw are limited. the aim of this study is to determine the immunogenicity of hpv vaccine in fsw and compare their antibody responses among young women (non-fsw) of the same age group by comparison with published data.

Eligibility criteria:
inclusion criteria: * each participant must meet all of the following criteria to be enrolled in this trial: * is between the reporting ages of 18-25 years at the time of recruitment * engage in commercial sex in the last month exclusion criteria: * participants meeting any of the following criteria will be excluded from the trial: * pregnant or possibly pregnant * has received any hpv vaccine previously * has an axillary temperate greater than 38°c * known allergies to any vaccine component * incapacity to provide consent

Keywords: hpv vaccine
predicting concussion outcomes with salivary mirna

Conditions: Concussion, Mild

Summary: the purpose of this study is to identify changes in salivary ribosomal nucleic acid (rna) expression that are predictive of symptom duration and character following mild traumatic brain injury (mtbi) in children.

the purpose of this study is to characterize longitudinal salivary rna expression in 600 children with mtbi and identify rna patterns that predict length and characterof concussive symptoms, as well as the response to therapy. hypothesis: specific rnas will be differentially regulated in children with prolonged mtbi symptoms across the acute and sub-acute time periods. the investigators predict that a set of rnas with differential expression in children with mtbi will be statistically associated with functional measures of mtbi symptoms as well as the duration of concussive symptoms. rationale: preliminary studies show that mirna is altered in adults with varying degrees of tbi and that salivary rna is altered by disorders of the cns. these studies indicate that serum-based mirna may be used as an accurate biomarker for differentiating adults with and without tbi. whether similar patterns can seen in the saliva of children following mtbi remains to be seen. furthermore, the influence of confounding variables such as gender, mechanism of injury, and previous mtbis on rna profiles has not been explored. the investigators propose to investigate these questions by examining salivary rna from 600 children (ages five to twenty-one years) with a clinical diagnosis of mtbi (as well as 100 age-and gender-matched controls, recruited from the penn state pediatric concussion clinic, emergency department, and the affiliated primary care clinics). the investigators plan to prospectively follow 600 children with mtbi for 1-month post-concussion, tracking subjective symptoms with the child sports concussion assessment tool (scat-5), and objective symptoms of balance and cognition. saliva will be collected via swab at three time-points (at initial clinical presentation, 1-2 weeks, and 4-weeks after the date of initial mtbi). expression of salivary rna taken at initial presentation will be compared against symptom duration (where prolonged post-concussive symptoms are defined as those lasting \>4 weeks) and character (as measured numerically by post-concussion symptom inventory self-report and clearedge scoring). the investigators plan to identify a set of salivary rnas that can easily be used to predict clinical course for pediatric patients following a diagnosis of mtbi.

Eligibility criteria:
inclusion criteria: * 5-21 years with mild traumatic brain injury that occurred within 7 days of enrollment exclusion criteria: * sever traumatic brain injury * skull fracture * concurrent upper respiratory infection * patients whose primary language is not english * periodontal infection * wards of the state * ongoing seizure disorder, * drug or alcohol dependency
the accuracy of static navigation systems and robotic system in partially edentulous in posterior area

Conditions: Dental Implant

Summary: the aim of this randomized clinical trial to compare the implant positional accuracy of robotic system-assisted implant surgery with that of static system-assisted implant surgery. patients will be recruited and randomly assigned to either the robotic surgery group or the static navigation surgery group to evaluate the accuracy of the implants in both groups and to compare patient-reported and physician-reported outcomes of the two approaches.

dental implants have been widely used for replacing the lost natural teeth, with evidence of long-term success and improvement of patients' quality of life. nevertheless, proper implant position is considered today an essential prerequisite for ensuring successful treatment outcomes, as well as long-term maintenance of the prosthesis and the peri-implant tissue health.therefore, we plan to conduct this randomized clinical trialto compare the implant positional accuracy of robotic system-assisted implant surgery with that of static system-assisted implant surgery. patients will be recruited and randomly assigned to either the robotic surgery group or the static navigation surgery group to evaluate the accuracy of the implants in both groups and to compare patient-reported and physician-reported outcomes of the two approaches.

Eligibility criteria:
inclusion criteria: * informed consent form signed voluntarily. * aged at least 18 years. * partial edentulousness in the posterior maxillary or mandibular region (premolar, molar, maximum two in a row). * sufficient bone volume for implant placement without bone augmentation; * the minimum number of residual teeth was seven teeth. * good communication with the physician, compliance, ability to follow the physician's advice to maintain oral hygiene. exclusion criteria: * systemic disease that would interfere with dental implant surgery. * bisphosphonate treatment. * untreated, uncontrolled periodontal disease. * heavy smoker (more than 10 cigarettes per day). * poor oral hygiene.

Keywords: dental implant robotic system static navigation system
an open-label trial with tmc125 in patients who have virologically failed in a duet trial (tmc125-c206 or tmc125-c216).

Conditions: HIV-1

Summary: the purpose of this trial is to evaluate the long-term safety and tolerability of tmc125 200 mg twice daily as part of an antiretroviral therapy including tmc114/rtv and an investigator selected optimized background in hiv-1 infected patients who have participated in a duet trial (tmc125-c206 or tmc125 c216) and have met the definition of virologic failure at week 24 or later in these trials.

this is a phase iii open-label, roll-over trial to evaluate the long term tolerability, safety, antiviral and immunological effect of tmc125 as part of an individually optimized antiretroviral therapy including tmc114/rtv in hiv-1 infected patients who participated in one of the duet (tmc125-c206 or tmc125-c216) trials. also the change in hiv-1 resistance over time will be evaluated. this trial offers patients meeting the definition of virologic failure at week 24 or beyond the option to roll-over to an open-label trial where they will receive tmc125 and tmc114/rtv. three hundred patients are estimated to enroll into this trial. the withdrawal visit of the duet trial will be the first visit of this trial. from this visit onward, all patients will receive 200 mg twice daily tmc125 and 600/100 mg twice daily tmc114/rtv until both tmc114 and tmc125 are commercially available or the therapy is no longer of clinical benefit to the patient. patients will receive an antiretroviral therapy consisting of tmc125 as the only non-nucleoside reverse transcriptase inhibitor (nnrti), tmc114/rtv as the only protease inhibitor (pi) and an optimized background, which will be selected by the investigator according to the local standard of care, the patient's experience with previous therapies and most recent resistance testing. the most recent hiv-1 genotype-analysis system report results from the duet trial will be made available. tmc125 will be dosed at 200 mg twice daily, administered orally as 2 tablets twice daily with food.tmc114/rtv will be dosed at 600/100 mg twice daily, administered orally as 2 tablets tmc114 and 1 capsule ritonavir twice daily with food.the optimized background will comprise of at least 1 approved arv drug: 1 or more nrti(s), with or without enf. administration will continue until both tmc114 and tmc125 are commercially available or therapy is no longer of clinical benefit to the patient.

Eligibility criteria:
inclusion criteria: * patient was previously randomized in a duet (tmc125-c206 or tmc125-c216) trial and completed at least 24 weeks of treatment * patient was virologically failing in a duet trial. exclusion criteria: * use of disallowed concomitant therapy * any grade 4 toxicity according to the division of aids (daids) grading table * patients who had to be withdrawn from the duet (tmc125-c206 or tmc125-c216) trials because of any of the mandatory withdrawal criteria of that trial.

Keywords: hiv-1 treatment experienced virologic failure
the effect of pumpkin seed extract capsules on nutritional status and haemoglobin level in pregnant women.

Conditions: Anemia During Pregnancy

Summary: the goal of this to measure the effect of supplementation of yellow pumpkin seed extract capsules in pregnant women on hemoglobin levels and nutritional status of pregnant women. the main question\[s\] it aims to answer are: * is there a difference in changes in nutritional status (increase in body weight and muac) in pregnant women who receive supplementation of pumpkin seed extract capsules and iron tablets * is there a difference in changes in hemoglobin levels in pregnant women who receive supplementation of pumpkin seed extract capsules and iron tablets. the research sample was divided into two groups, namely the intervention group and the control group. in the intervention group, pregnant women received pumpkin seed extract capsules for 12 weeks, while the control group received iron tablets for 12 weeks as well. measurements of nutritional status (including measurements of body weight and mid upper arm circumference/muac) were carried out before and after the intervention and were monitored every month until 12 weeks when the intervention was carried out. as for measuring blood hemoglobin levels, it was taken before the intervention and after the intervention for 12 weeks

this study was designed with an experimental method using a randomized double blind with a control group. the research sample was divided into two groups, namely the intervention group and the control group. in the intervention group, pregnant women received pumpkin seed extract capsules for 12 weeks, while the control group received iron tablets for 12 weeks as well. measurements of nutritional status (including measurements of body weight and mid upper arm circumference/muac) were carried out before and after the intervention and were monitored every month until 12 weeks when the intervention was carried out. as for measuring blood hemoglobin levels, it was taken before the intervention and after the intervention for 12 weeks. the research will be conducted in the village of the stunting locus, bone regency, south sulawesi, indonesia. data analysis was carried out with spss, where to see the difference between the intervention group and the contro group, a paired t test was used if the data was normally distributed and an alternative test if the data was not normally distributed.

Eligibility criteria:
inclusion criteria: 1. in the one or second trimester of pregnancy; 2. having no complications; 3. willing to participate in this study; 4. domiciled in the stunting locus village bone regency . exclusion criteria: * pregnant women with complications
improving spine surgical care with real-time objective patient tracking using the apple watch

Conditions: Spine Disease; Spine Degeneration; Spinal Stenosis; Surgery; Spine Fusion

Summary: one of the primary goals of spine surgery is to reduce pain and increase mobility to improve patients' quality of life. currently, there is no established method for surgeons to objectively track their patients' mobilization postoperatively. this study is the first prospective trial utilizing the apple watch to objectively track patients before and after elective spine surgery. the investigators hypothesize that the ability of patients to track their own activity and discuss with their surgeon objective mobilization goals will not only help patients achieve empowerment in their own care but also improve their overall satisfaction and self-reported outcomes after spine surgery.


Eligibility criteria:
inclusion criteria: * english-speaking. * undergoing elective spine surgery by attending physicians at stanford university. * own iphone exclusion criteria: * patients with spine trauma, tumors, or infection.

Keywords: spine surgery apple watch objective tracking of spine surgery outcomes
wideband tympanometry for monitoring intracranial pressure in adult patients in intensive care, operated on for an intracranial lesion after traumatic brain injury, or with intracranial hemorrhage

Conditions: Intracranial Pressure

Summary: intracranial pressure is usually measured by invasive methods requiring an intracranial sensor. there is no non-invasive monitoring method recognized as a gold standard. tympanometry would make it feasible to evaluate intracranial pressure through sensitive and specific changes in the energy absorbance of the middle ear. it could represent a non-invasive method of monitoring intracranial pressure. this is a prospective monocentric longitudinal study. all adult patients in intensive care for head trauma, intracranial hypertension, or after cranial surgery and requiring invasive monitoring of icp will be included after their non-opposition has been collected. in a group of 10 controls, multifrequency tympanometry will be performed in the standing position, in the 0° supine position and in the tredelenburg position at -17°.


Eligibility criteria:
inclusion criteria: patients: * person who did not oppose to their inclusion in the trial * head trauma, patient operated on for an intracranial lesion, or other condition (hemorrhagic stroke...) requiring monitoring of icp by a subdural or epidural sensor. * age \> 18 years old controls: * person who did not oppose to their inclusion in the trial * age \> 18 years old * no otologic or neurological history. exclusion criteria: * person subject to a measure of legal protection (curatorship, guardianship) * person under judicial control * pregnant, parturient or breastfeeding woman * minor * fracture of the petrosal bone, abnormality of the bilateral middle or inner ear or canal preventing tympanometry
high-definition transcranial electrical stimulation for lower limb stroke rehabilitation

Conditions: Stroke

Summary: transcranial electrical stimulation (tces) is a non-invasive and safe treatment, which uses a low direct current or alternating current to change the excitability of the cerebral cortex. the tces has been applied in clinical trials related to rehabilitation research in recent years, and the safety and effectiveness have also been established. however, the existing tces products effect on the whole brain networks and lack special waveforms. we developed a wearable high-definition tces (hd-tces) with special waveforms. this novel stimulation system will result in more precise and focal stimulation of selected brain regions with special waveforms to display better neuromodulation performance. in this study, we will preliminarily examine the effects and safety of the hd-tces on lower extremity in patients with stroke. we expect that the hd-tces combined with the lower extremity rehabilitation can shorten the duration of rehabilitative periods, improve stroke patients' activity of daily living, reduce the care burden of patients' family, and subsequently decrease the cost of health care insurance.


Eligibility criteria:
inclusion criteria: 1. with a diagnosis of stroke. 2. age ≥ 20 years. 3. hemiplegia, brunnstrom stage iii-v. 4. 6 months to 5 years after stroke. 5. muscular inelasticity (spasticity) 1-3 on the affected lower limb, evaluated by the modified ashworth scale. 6. ability to walk for 10 min non-stop with no gait aids or ability to walk 20 m with supervision or slight assistance. exclusion criteria: 1. intolerance to electrical stimulation. 2. contracture on lower extremities, and limitation in joint range of motion. 3. severe spasticity. 4. ossification or inflammation in muscle tissue. 5. a history of arrhythmia. 6. implantable medical electronic devices (e.g., like pacemaker). 7. metal implants in the head or neck. 8. wounds on the skin of head. 9. a history of brain surgery or severe brain trauma. 10. severe cognitive or psychiatric disorders (e.g., schizophrenia, depression or bipolar disorder). 11. a history of seizure or other brain pathology. 12. drug or alcohol abuse. 13. malignant neoplasm or rheumatism disorder (e.g., sle, ra, as, ibd) 14. undergoing other non-invasive brain stimulation. 15. intra-cerebral lesions (such as brain tumors, arteriovenous tumors). 16. history of encephalitis or meningitis. 17. stroke lesion in cerebellum or brainstem. 18. leg amputation. 19. sleep deprivation. 20. severe or recent heart disease. 21. subjects who use drugs that may lower the seizure threshold. 22. pregnant or breastfeeding women.

Keywords: stroke, transcranial electrical stimulation, lower-limb rehabilitation
a study of pemetrexed/cisplatin as pre-operative treatment of early stage nonsquamous non-small cell lung cancer

Conditions: Non Small Cell Lung Cancer

Summary: the purpose of this trial is to assess how well the combination of pemetrexed with cisplatin can reduce tumor size.


Eligibility criteria:
inclusion criteria: * nonsquamous non-small cell lung cancer that was confirmed by tissue biopsy * stage iiian2 disease (t1an2, t1bn2, t2an2, t2bn2, and t3n2) * tumor considered potentially resectable * good performance status (score of 0 or 1) according to eastern cooperative oncology group scale (ecog) * no prior therapy for lung cancer * measurable disease according to version 1.1 of response evaluation criteria in solid tumors (recist) criteria * life expectancy of at least 6 months * organs are functioning well (bone marrow reserve, liver, kidney, lung) * signed informed consent * women must be surgically sterile, postmenopausal, or compliant with a medically approved contraceptive regimen (for example, intrauterine device, birth control pills, or barrier device) during and for 6 months after last dose of study drug; must have a negative pregnancy test within 7 days before study enrollment; and must not be breast-feeding. * men must be surgically sterile, or compliant with a contraceptive regimen during and for 6 months after last dose of study drug. * be fit for surgery at the time of enrollment exclusion criteria: * receiving or have received an investigational drug or device within the last 30 days * have previously completed or withdrawn from this study or any other study investigating pemetrexed * serious concomitant systemic disorder * serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease * receiving concurrent administration of any other anticancer therapy * have received a recent (within 30 days of enrollment) or are receiving concurrent yellow fever vaccination * inability or unwillingness to take pemetrexed supplementation/premedication (folic acid, vitamin b12, or corticosteroids) * inability to interrupt aspirin or other nonsteroidal anti-inflammatory agents, other than an aspirin dose less than or equal to 1.3 grams per day
placental membrane for root coverage

Conditions: Gingival Recession

Summary: aim of the study was to evaluate the clinical efficacy of placental membrane with coronally advanced flap in covering single and multiple miller's class i and ii gingival recession defects.

study design a total number of 60 teeth in 15 subjects were selected. patients with bilateral miller's class i and ii gingival recession defects in the maxillary or mandibular anterior and premolar region were selected and divided into two groups using a split mouth design. groupi (control) -30 recession defects treated with coronally advanced flap alone, using zucchelli's technique. group ii (test) - 30 recession defects treated with coronally advanced flap, using zucchelli's technique along with placental membrane. . clinical parameters: 1. probing pocket depth(ppd) 2. clinical attachment level(cal) 3. height of gingival recession(hgr) 4. width of gingival recession(wgr) 5. width of keratinized gingiva(wkg) the clinical parameters were assessed \& recorded on 0 day, 90th day and 180th day

Eligibility criteria:
inclusion criteria: 1. patients within the age group 23 to 55 years 2. bilateral, upper or lower, miller's class i and class ii gingival recession defects confined to the anterior and premolar region. 3. presence of identifiable cemento-enamel junction 4. presence of keratinized tissue apical to the exposed root exclusion criteria: 1. systemic complications 2. occlusal interferences 3. any contraindication for periodontal surgery and taking medication which are known to interfere with periodontal tissue health or healing 4. previous periodontal surgery on the involved site 5. smokers 6. pregnant and lactating mothers

Keywords: gingival recession zuchellis technique, placental membrane